Jump to content

Eluxadoline

From Wikipedia, the free encyclopedia
(Redirected from Viberzi)
Eluxadoline
Clinical data
PronunciationViberzi (/vaɪˈbɜːrzi/ vy-BUR-zee
Trade namesViberzi, Truberzi
Other namesJNJ-27018966
Routes of
administration		By mouth
ATC code
Legal status
Legal status
Pharmacokinetic data
Protein binding81%
Elimination half-life3.7–6 hours
Excretion82.2% (feces), <1% (urine)[2]
Identifiers
  • 5-({[(2S)-2-amino-3-(4-carbamoyl-2,6-dimethylphenyl)propanoyl] [(1S)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]amino}methyl)-2-methoxybenzoic acid
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC32H35N5O5
Molar mass569.662 g·mol−1
3D model (JSmol)
  • CC1=CC(=CC(=C1CC(C(=O)N(CC2=CC(=C(C=C2)OC)C(=O)O)C(C)C3=NC=C(N3)C4=CC=CC=C4)N)C)C(=O)N
  • InChI=1S/C32H35N5O5/c1-18-12-23(29(34)38)13-19(2)24(18)15-26(33)31(39)37(17-21-10-11-28(42-4)25(14-21)32(40)41)20(3)30-35-16-27(36-30)22-8-6-5-7-9-22/h5-14,16,20,26H,15,17,33H2,1-4H3,(H2,34,38)(H,35,36)(H,40,41)/t20-,26-/m0/s1
  • Key:QFNHIDANIVGXPE-FNZWTVRRSA-N

Eluxadoline, sold under the brand names Viberzi and Truberzi,[3] is a medication taken by mouth for the treatment of diarrhea and abdominal pain in individuals with diarrhea-predominant irritable bowel syndrome (IBS-D).[4] It was approved for use in the United States in 2015.[5] The drug originated from Janssen Pharmaceutica and was developed by Actavis.

Contraindications

[edit]

This drug is contraindicated in case of having:

Adverse effects

[edit]

Common adverse effects are constipation and nausea, but rates of discontinuation due to constipation were low for both eluxadoline and placebo. Rare adverse effects: fatigue, bronchitis, viral gastroenteritis. Rare serious adverse effects include pancreatitis with a general incidence of 0.3%: higher incidence with 100 mg dose (0.3%) than with 75 mg dose (0.2%).[7] The risk is even greater in those who do not have a gallbladder and the medication is not recommended in this group.[8]

In March 2017, the U.S. Food and Drug Administration issued a safety alert for eluxadoline concerning an increased risk of serious pancreatitis in patients without a gallbladder.[9] An FDA review found that in such patients, spasm of the sphincter of Oddi may lead to severe pancreatitis.[10] The FDA reported that in some cases symptoms have occurred with just one or two doses at the recommended dosage for patients without a gallbladder (75 mg).[10] Of two deaths associated with eluxadoline reported up to February 2017, both occurred in patients without a gallbladder.[9]

Interactions

[edit]

Elevated concentrations of eluxadoline were observed with co-administration of inhibitors of the transporter protein OATP1B1, such as ciclosporin, gemfibrozil, certain antiretrovirals, rifampicin, and eltrombopag.[medical citation needed]

Concurrent use of other drugs that cause constipation, such as opioids, alosetron, anticholinergics, and bismuth subsalicylate, is not preferred.[11]

Eluxadoline increases the concentrations of drugs which are OATP1B1 and BCRP substrates.[medical citation needed] Co-administration of eluxadoline with rosuvastatin may increase the risk of rhabdomyolysis.[2]

Pharmacology

[edit]

Mechanism of action

[edit]

Eluxadoline is a μ- and κ-opioid receptor agonist and δ-opioid receptor antagonist[12] that acts locally in the enteric nervous system, possibly decreasing adverse effects on the central nervous system.[13][14]

Pharmacokinetics

[edit]

In the in vitro studies, eluxadoline was found to be transported by OAT3 (SLC22A8), OATP1B1 (SLCO1B1), and BSEP (ABCB11) at the highest concentrations tested (400 ng/ml, which is 162-fold larger than the observed Cmax of the highest therapeutic dose of 100 mg). However, it was not to be transported by OCT1 POU2F1, OAT1 (organic anion transporter 1), OCT2, OATP1B3 (SLCO1B3), P-gp (P-glycoprotein), or BCRP (ABCG2).

Multidrug resistance-associated protein 2 (MRP2)-vesicular accumulation of eluxadoline was observed, indicating that the drug is a substrate of MRP2. Eluxadoline was not found to inhibit BCRP-, BSEP-, MRP2-, OCT1-, OCT2-, OAT1-, OAT3-, or OATP1B3-mediated transport of probe substrates but inhibited the transport of probe substrates of OATP1B1 and P-gp. In the in vitro studies, it was observed that eluxadoline is an in vivo substrate of OATP1B1, OAT3, and MRP2. Finally, no inhibition or induction of cytochrome P450 enzymes was observed.[15]

Following a 100 mg dose of eluxadoline, the Cmax was about 2 to 4 ng/ml and AUC was 12 to 22 ng.h/ml. Eluxadoline has linear pharmacokinetics with no accumulation upon repeated twice daily dosing. Taking eluxadoline with high fat meal decreased the Cmax by 50% and AUC by 60%.[2]

Chemistry

[edit]

Synthesis

[edit]

The synthesis of eluxadoline was published in 2006.[16]

References

[edit]
  1. ^ "Digestive and bladder health". Health Canada. 9 May 2018. Retrieved 13 April 2024.
  2. ^ a b c d "Viberzi- eluxadoline tablet, film coated". DailyMed. 24 July 2024. Retrieved 11 November 2024.
  3. ^ "Truberzi". European Medicines Agency. 29 September 2016. Archived from the original on 21 September 2017. Retrieved 28 June 2017.
  4. ^ Fragkos KC (2017-09-25). "Spotlight on eluxadoline for the treatment of patients with irritable bowel syndrome with diarrhea". Clinical and Experimental Gastroenterology. 10: 229–240. doi:10.2147/ceg.s123621. PMC 5624596. PMID 28989282.
  5. ^ "FDA approves two therapies to treat IBS-D". www.fda.gov. Retrieved 2015-06-01.[dead link‍]
  6. ^ "Eluxadoline Monograph for Professionals". Drugs.com. 10 May 2024. Retrieved 11 November 2024.
  7. ^ Lembo AJ, Lacy BE, Zuckerman MJ, Schey R, Dove LS, Andrae DA, et al. (January 2016). "Eluxadoline for Irritable Bowel Syndrome with Diarrhea". The New England Journal of Medicine. 374 (3): 242–53. doi:10.1056/NEJMoa1505180. PMID 26789872. S2CID 205098220.
  8. ^ Office of the Commissioner (15 March 2017). "Safety Alerts for Human Medical Products - Viberzi (eluxadoline): Drug Safety Communication - Increased Risk of Serious Pancreatitis In Patients Without A Gallbladder". www.fda.gov. Archived from the original on 25 April 2018. Retrieved 19 March 2017.
  9. ^ a b Brooks M (March 2017). "FDA: Avoid IBS Drug Viberzi in Patients With No Gallbladder". www.medscape.com. Retrieved 2017-09-18.
  10. ^ a b Office of the Commissioner. "Safety Alerts for Human Medical Products - Viberzi (eluxadoline): Drug Safety Communication - Increased Risk of Serious Pancreatitis In Patients Without A Gallbladder". www.fda.gov. Retrieved 2017-09-18.
  11. ^ "bismuth subsalicylate". Medscape. Retrieved 2016-05-10.
  12. ^ Levy-Cooperman N, McIntyre G, Bonifacio L, McDonnell M, Davenport JM, Covington PS, et al. (December 2016). "Abuse Potential and Pharmacodynamic Characteristics of Oral and Intranasal Eluxadoline, a Mixed μ- and κ-Opioid Receptor Agonist and δ-Opioid Receptor Antagonist". The Journal of Pharmacology and Experimental Therapeutics. 359 (3): 471–481. doi:10.1124/jpet.116.236547. PMC 5118645. PMID 27647873.
  13. ^ "Actavis Announces FDA Acceptance for Filing of NDA for Eluxadoline". www.drugs.com. Retrieved 2015-06-01.
  14. ^ "FDA Approves Viberzi (eluxadoline) for Irritable Bowel Syndrome with Diarrhea (IBS-D) in Adults". www.drugs.com. Retrieved 2015-06-01.
  15. ^ Davenport JM, Covington P, Bonifacio L, McIntyre G, Venitz J (May 2015). "Effect of uptake transporters OAT3 and OATP1B1 and efflux transporter MRP2 on the pharmacokinetics of eluxadoline". Journal of Clinical Pharmacology. 55 (5): 534–42. doi:10.1002/jcph.442. PMC 4402028. PMID 25491493.
  16. ^ [1], Process of the Preparation of Opioid modulators.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Eluxadoline&oldid=1256863241"